NovoCure NVCR Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from NovoCure’s reported figures.
Based on trailing twelve months.
The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about NovoCure's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NovoCure's return on equity?
- NovoCure (NVCR) reported return on equity of -50% in Q1 2026.
- How has NovoCure's return on equity changed year-over-year?
- NovoCure's return on equity decreased by 9.8% year-over-year, from -45.5% to -50%.
- What is the long-term trend for NovoCure's return on equity?
- Over 5 years (2020 to 2025), NovoCure's return on equity has grown at a 46.8% compound annual growth rate (CAGR), from 5.7% to -38.9%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.